Literature DB >> 24458020

Testing safety of germinated rye sourdough in a celiac disease model based on the adoptive transfer of prolamin-primed memory T cells into lymphopenic mice.

Tobias L Freitag1, Jussi Loponen, Marcel Messing, Victor Zevallos, Leif C Andersson, Tuula Sontag-Strohm, Päivi Saavalainen, Detlef Schuppan, Hannu Salovaara, Seppo Meri.   

Abstract

UNLABELLED: The current treatment for celiac disease is strict gluten-free diet. Technical processing may render gluten-containing foods safe for consumption by celiac patients, but so far in vivo safety testing can only be performed on patients. We modified a celiac disease mouse model to test antigenicity and inflammatory effects of germinated rye sourdough, a food product characterized by extensive prolamin hydrolysis. Lymphopenic Rag1-/- or nude mice were injected with splenic CD4+CD62L-CD44high-memory T cells from gliadin- or secalin-immunized wild-type donor mice. We found that: 1) Rag1-/- recipients challenged with wheat or rye gluten lost more body weight and developed more severe histological duodenitis than mice on gluten-free diet. This correlated with increased secretion of IFNγ, IL-2, and IL-17 by secalin-restimulated splenocytes. 2) In vitro gluten testing using competitive R5 ELISA demonstrated extensive degradation of the gluten R5 epitope in germinated rye sourdough. 3) However, in nude recipients challenged with germinated rye sourdough (vs. native rye sourdough), serum anti-secalin IgG/CD4+ T helper 1-associated IgG2c titers were only reduced, but not eliminated. In addition, there were no reductions in body weight loss, histological duodenitis, or T cell cytokine secretion in Rag1-/- recipients challenged accordingly. IN
CONCLUSION: 1) prolamin-primed CD4+CD62L-CD44high-memory T cells induce gluten-sensitive enteropathy in Rag1-/- mice. 2) Hydrolysis of secalins in germinated rye sourdough remains incomplete. Secalin peptides retain B and T cell stimulatory capacity and remain harmful to the intestinal mucosa in this celiac disease model. 3) Current antibody-based prolamin detection methods may fail to detect antigenic gluten fragments in processed cereal food products.

Entities:  

Keywords:  B cell; enteropathy; gluten; small intestine

Mesh:

Substances:

Year:  2014        PMID: 24458020     DOI: 10.1152/ajpgi.00136.2013

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  5 in total

1.  Gliadin Nanoparticles Induce Immune Tolerance to Gliadin in Mouse Models of Celiac Disease.

Authors:  Tobias L Freitag; Joseph R Podojil; Ryan M Pearson; Frank J Fokta; Cecilia Sahl; Marcel Messing; Leif C Andersson; Katarzyna Leskinen; Päivi Saavalainen; Lisa I Hoover; Kelly Huang; Deborah Phippard; Sanaz Maleki; Nicholas J C King; Lonnie D Shea; Stephen D Miller; Seppo K Meri; Daniel R Getts
Journal:  Gastroenterology       Date:  2020-02-04       Impact factor: 22.682

Review 2.  Lessons from rodent models in celiac disease.

Authors:  N Korneychuk; B Meresse; N Cerf-Bensussan
Journal:  Mucosal Immunol       Date:  2014-10-29       Impact factor: 7.313

3.  Identification of food-grade subtilisins as gluten-degrading enzymes to treat celiac disease.

Authors:  Guoxian Wei; Na Tian; Roland Siezen; Detlef Schuppan; Eva J Helmerhorst
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-07-28       Impact factor: 4.052

Review 4.  Celiac Disease: A Review of Current Concepts in Pathogenesis, Prevention, and Novel Therapies.

Authors:  Jason A Tye-Din; Heather J Galipeau; Daniel Agardh
Journal:  Front Pediatr       Date:  2018-11-21       Impact factor: 3.418

5.  Selection of Gut-Resistant Bacteria and Construction of Microbial Consortia for Improving Gluten Digestion under Simulated Gastrointestinal Conditions.

Authors:  Maria De Angelis; Sonya Siragusa; Mirco Vacca; Raffaella Di Cagno; Fernanda Cristofori; Michael Schwarm; Stefan Pelzer; Monika Flügel; Bodo Speckmann; Ruggiero Francavilla; Marco Gobbetti
Journal:  Nutrients       Date:  2021-03-19       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.